Preclinical and clinical trials investigating the combination of CDK4/6 inhibitors with ICIs for breast cancer suggest that combined use does not significantly enhance responses compared to CDK4/6 inhibitor monotherapy [129]. This evidence concerns the gene CDK4 and breast carcinoma.